Image

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Recruiting
18 years of age
Both
Phase 2

Powered by AI

Overview

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Description

The purpose of this randomized, double-blind study is to investigate the efficacy and safety of NS229 compared with placebo over a 28-week study treatment period in subjects with Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving background corticosteroid therapy with or without mepolizumab therapy. During the treatment period corticosteroid dose will be tapered.

The key outcomes in the study focus on evaluation of clinical remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of <=4 mg/day prednisolone/prednisone.

Eligibility

Inclusion Criteria:

  • Ability to provide written informed consent prior to participation in the study.
  • Male or female subjects aged ≥18 years at the time the informed consent form is signed.
  • Diagnosis of EGPA: Subjects who have been diagnosed with EGPA based on the history or presence of eosinophilia plus at least a history or presence of 2 of additional features of EGPA.
  • Use of adequate contraception.
  • Other inclusion criteria may apply.

Exclusion Criteria:

  • Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis
  • Imminently life-threatening EGPA at the time of screening.
  • History or presence of any form of cancer within 5 years prior to screening.
  • Serious liver, renal, blood, or psychiatric disease
  • Severe or clinically significant cardiovascular disease uncontrolled with standard treatment
  • Active systemic infections (including TB, pneumonia, Pneumocystis pneumonia, sepsis, and opportunistic infections)
  • Parasitic infection: Subjects with a known parasitic infestation within 6 months prior to screening.
  • HIV positive status
  • Active hepatitis due to hepatitis B virus or hepatitis C virus
  • Known history or presence of venous thromboembolism/venous thrombotic events (deep vein thrombosis and/or pulmonary embolus)
  • laboratory parameter exclusions:
    1. Estimated glomerular filtration rate of <30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equations
    2. WBC count <4 × 109/L
    3. Absolute lymphocyte count <500 cells/mm3
    4. Absolute neutrophil count <500 cells/mm3
    5. Platelet count <120,000/mm3
    6. Hemoglobin <8 g/dL (<80 g/L)
  • Subjects who are pregnant, breastfeeding, or planning to become pregnant during the

    time of study participation

  • History of clinically significant drug or alcohol abuse within the last 6 months
  • Other exclusion criteria may apply.

Study details

Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome

NCT06046222

NS Pharma, Inc.

3 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.